David Satinsky, M.D. - Retired

Biography : 

The Neurology Center salutes Dr. David Satinsky for 48 years of providing excellent neurological care. Dr. Satinsky retired from the practice of medicine at the end of June, 2019. We wish him much health and happiness in the years ahead. Congratulations!

Dr. David Satinsky is a graduate of the University of Pennsylvania School of medicine. He completed his residency in neurology at the Hospital of the University of Pennsylvania and was a Research Associate at the National Institutes of Health. He is board certified in neurology and electroencephalography. He is a member of the American Academy of Neurology.

Curriculum Vitae : 

Retired as of June 27, 2019

BUSINESS TELEPHONE: (301) 562-7200
District of Columbia
CERTIFICATION: American Board of Psychiatry & Neurology, 1972
American Board of Qualification in Eectroencephalography, June 1977
UNDERGRADUATE University of Pennsylvania
B.A. in Chemistry
September 1956 to June 1960

NSF training grant in biochemistry
University of Pennsylvania School of Medicine
Sponsor: Dr. Adelaide Delluva
Summer 1959

MEDICAL SCHOOL University of Pennsylvania School of Medicine
M.D., 1964

Part-time research in ultrastructure of peripheral nerve
University of Pennsylvania Department of Anatomy
Sponsors: Dr. Frank Pepe and Dr. C.N. Liu
1960 to 1964

INTERNSHIP Bronx Municipal Hospital Center
Straight Medical Internship
July 1964 to June 1965
RESIDENCY Hospital of the University of Pennsylvania
Neurology Resident
July 1967 to June 1970
MILITARY SERVICE National Institutes of Mental Health
Washington, D.C.
July 1965 to June 1967
1970 to 1971 Private Practice, Neurology
Riverdale, Maryland
1971 to 2019 Private Practice, Neurology-Retired
The Neurology Center, Rockville, Maryland
1970 to 1972 Attending Neurologist
National Children's Rehabilitation Center
Leesburg, Virginia
1979 to 1985 Director, Headache Clinic
The Neurology Center
Chevy Chase, Maryland
1985 to 1986 Board Member
Center for Unique Learners
Alpha Epsilon Delta
(President of the Epsilon Chapter, 1959-60)
Pi Mu Epsilon (mathematics)
Alpha Omega Alpha (President, 1963-64)
Alpha Chi Sigma (chemistry)
PROFESSIONAL SOCIETIES: American Epilepsy Society
American Association for the Study of Headache
American Board of Clinical Biofeedback
American Academy of Neurology
American Medical Association
Montgomery County Medical Society
American Electroencephalographic Society
FACULTY: Assistant Clinical Professor of Neurology,
George Washington University School of Medicine
1971 - present

Satinsky, D., Pepe, F.A., and Lieu, C.N., The Neurilemma Cell in Peripheral Nerve Degeneration and Regeneration. Exp. Neurol., 9: 441-451, 1964

Satinsky, D. and Salmoiraghi, G.C., Pharmacology of Lateral Geniculate Nucleus Neurons. Fed. Proc., No. 2, 1967

Satinsky, D., Pharmacological Responsiveness of Lateral Geniculate Nucleus Neurons. Int. J. Neuropharm. 6: 3870397, 1967

Satinsky, D., Reticular Influences on Lateral Geniculate Neuron Activity. Electroenceph. Clin. Neurophysiol. 25: 543-549, 1968

Uhlman, F.W. and Satinsky, D., Games Patients Play. Pract Psychol, 37, 1977

Satinsky, D. “Neurology,” in Medicine: Pretest Self-Assessment and Review, 2nd ed., ed by Dwyer, J.M. and Miller, D.J., McGraw-Hill, New York,, 1982

Satinsky, D., Evolution and Evaluation of Group Medical Practice. Seminars in Neurol, 5: 46-49, 1985


Benjamin Franklin Scholar, 1956-60

Addison Award for research in anatomical sciences, 1963

Research Associate at NIMH, July 1965 to June 1967 with Dr. G. C. Salmoiraghi, Director, Division of Special Mental Health Research Services, Wash., D.C.

Armed Forces Institute of Pathology Neuropathology Course, February 1969

Course in pediatric neurology at the Neurological Institute, New York, May 1969



CN102-021 - “A Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Butophanol Tartrate Nasal Spray Versus Acetaminophen and Codeine Phosphate Capsules Versus Placebo in Patients with Acute Migraine Headache Pain.”


CN115-038-031 - “An Open Label Long-Term Trial Evaluating the Safety of BMS-180048 150 mg in the Treatment of Patients with Migraine Headache With or Without Aura.”


Copolymer I Protocol 01-9002 - “A Long-Term, Open Label Study to Evaluate the Safety of Copolymer I and to Extend Its Availability to Patients with Relapsing-Remitting Multiple Sclerosis.”


S2WA 1007 - “A Study to Evaluate the Pharmocokinetics and Pharmacodynamics of Oral Naratriptan in Migraine Subjects.”


S2WA 3001 - “A Randomized, Double-Blind, Placebo-Controlled, Dose Regulated Study to Evaluate the Efficacy and Safety of Four Doses of Oral Naratriptan in the Acute Treatment of a Single Migraine Attack.”